HBcAg |
|
Vaxjo ID |
313 |
|
Vaccine Adjuvant Name |
HBcAg |
|
Adjuvant VO ID |
VO_0005270
|
|
Description |
A non-human hepadnaviral adjuvant derived from stork hepatitis B virus core gene-sequences, used in hepatitis C virus-based genetic vaccines. It is designed to enhance HCV-specific IFN-纬 and IL-2 responses and induce long-term functional memory T cell responses, avoiding potential interference from pre-existing immunity to human HBV. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Human hepatitis B virus (HBV) core antigen (HBcAg) can act as an adjuvant in hepatitis C virus (HCV)-based DNA vaccines. |
|
Structure |
Full-length and fragmented gene-sequences. |
|
Preparation |
Full-length and fragmented stork HBcAg gene-sequences were added to an HCV non-structural (NS) 3/4A gene to create NS3/4A-stork-HBcAg. |
|
Function |
The NS3/4A-stork-HBcAg vaccine enhanced HCV-specific IFN-γ and IL-2 responses in both normal and NS3/4A-transgenic mice with dysfunctional T cells. Repeated doses boosted these T cell responses and induced long-term memory dependent on CD4(+) T cells. Thus, stork-derived avian HBcAg sequences serve effectively as a DNA vaccine adjuvant. |
|
Safety |
The adjuvant "completely avoids the use of sequences from a human virus where a pre-existing immunity may interfere with its adjuvant effect", implying a safety advantage by circumventing potential immune interference. |
| Related Vaccine(s) |
|
| References |
Levander et al., 2016: Levander S, Sällberg M, Ahlén G, Frelin L. A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines. Vaccine. 2016; 34(25); 2821-2833. [PubMed: 27109565].
|
